Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Thorac Cancer. 2022 Jul;13(14):2005-2013. doi: 10.1111/1759-7714.14477. Epub 2022 Jun 9.
To evaluate the long-term outcomes after surgical resection for stage I lung adenocarcinoma based on the percentage of lepidic component (LC) and invasive tumor size (IS).
The clinicopathological characteristics of 1049 patients with stage I lung adenocarcinoma who underwent surgery between 2006 and 2016 were retrospectively reviewed. Tumors were categorized into groups: A (LC ≥ 50%) and B (LC < 50%). Groups A0 and A1 consisted of minimally invasive adenocarcinomas (MIA) and other lepidic-predominant invasive adenocarcinomas, respectively. Group B was categorized into B1 (IS ≤ 1 cm), B2 (1 < IS≤2 cm), and B3 (2 < IS≤3 cm) by invasive tumor size and divided into subgroups (B1[lep+]/[lep-], B2[lep+]/[lep-], and B3[lep+]/[lep-]) according to the presence[lep+] or absence[lep-] of LCs. Cumulative incidence of recurrence (CIR) and cancer-specific survival (CSS) were examined.
LC decreased with increasing IS. Only 24 (8.5%) tumors in group A had an IS >1 cm. 10-year CIR and CSS were 15.2% and 86.0%. LC and IS were found to be independent predictors of CSS. Patients in group A had 1.4% 10-year CIR and 100% 10-year CSS. In group B, a significantly higher CIR and worse CSS were observed as IS increased (p < 0.001), but LC was not a predictor for CSS (p = 0.593). No significant differences in CIR or CSS were found in presence of LC or not when LC < 50% (B1[lep+]/[lep-], B2[lep+]/[lep-], and B3[lep+]/[lep-]: p = 0.36/0.48, p = 0.82/0.94, and p = 0.90/0.37, respectively).
LC≥50% tumors demonstrated excellent prognosis regardless of IS. The outcomes of LC < 50% tumors were well predicted by IS, corresponding to the T-staging system. The predictive value of LC for prognosis became insignificant.
本研究旨在评估基于贴壁成分(LC)百分比和浸润性肿瘤大小(IS)的肺腺癌 I 期患者的长期预后。
回顾性分析了 2006 年至 2016 年间接受手术治疗的 1049 例肺腺癌 I 期患者的临床病理特征。肿瘤分为 A 组(LC≥50%)和 B 组(LC<50%)。A0 组和 A1 组分别由微浸润腺癌(MIA)和其他贴壁为主的浸润性腺癌组成。B 组根据浸润性肿瘤大小进一步分为 B1(IS≤1cm)、B2(1cm<IS≤2cm)和 B3(2cm<IS≤3cm),并根据 LC 的存在与否(B1[lep+]/[lep-]、B2[lep+]/[lep-]和 B3[lep+]/[lep-])进行亚组分析。检测累积复发率(CIR)和癌症特异性生存率(CSS)。
LC 随 IS 的增加而降低。A 组中仅有 24 例(8.5%)肿瘤 IS>1cm。10 年 CIR 和 CSS 分别为 15.2%和 86.0%。LC 和 IS 是 CSS 的独立预测因子。A 组患者的 10 年 CIR 为 1.4%,CSS 为 100%。随着 IS 的增加,B 组患者的 CIR 和 CSS 显著降低(p<0.001),但 LC 不是 CSS 的预测因子(p=0.593)。当 LC<50%时,LC 的存在与否对 CIR 或 CSS 无显著影响(B1[lep+]/[lep-]、B2[lep+]/[lep-]和 B3[lep+]/[lep-]:p=0.36/0.48,p=0.82/0.94,p=0.90/0.37)。
LC≥50%的肿瘤无论 IS 如何,均具有良好的预后。LC<50%的肿瘤预后可通过 IS 准确预测,与 T 分期系统相对应。LC 对预后的预测价值变得不显著。